156 related articles for article (PubMed ID: 9569015)
1. Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders.
Battmann T; Branche C; Bouchoux F; Cerede E; Philibert D; Goubet F; Teutsch G; Gaillard-Kelly M
J Steroid Biochem Mol Biol; 1998 Jan; 64(1-2):103-11. PubMed ID: 9569015
[TBL] [Abstract][Full Text] [Related]
2. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
3. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Simard J; Singh SM; Labrie F
Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
[TBL] [Abstract][Full Text] [Related]
4. ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
Furr BJ
Prog Clin Biol Res; 1988; 260():13-26. PubMed ID: 2966405
[No Abstract] [Full Text] [Related]
5. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Sarosdy MF
Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288
[TBL] [Abstract][Full Text] [Related]
6. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor.
Teutsch G; Goubet F; Battmann T; Bonfils A; Bouchoux F; Cerede E; Gofflo D; Gaillard-Kelly M; Philibert D
J Steroid Biochem Mol Biol; 1994 Jan; 48(1):111-9. PubMed ID: 8136296
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
9. Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity.
Luo S; Martel C; Chen C; Labrie C; Candas B; Singh SM; Labrie F
Urology; 1997 Dec; 50(6):913-9. PubMed ID: 9426723
[TBL] [Abstract][Full Text] [Related]
10. The development of Casodex (bicalutamide): preclinical studies.
Furr BJ
Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
[TBL] [Abstract][Full Text] [Related]
11. Vinclozolin and p,p'-DDE alter androgen-dependent gene expression: in vivo confirmation of an androgen receptor-mediated mechanism.
Kelce WR; Lambright CR; Gray LE; Roberts KP
Toxicol Appl Pharmacol; 1997 Jan; 142(1):192-200. PubMed ID: 9007049
[TBL] [Abstract][Full Text] [Related]
12. ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen.
Furr BJ; Valcaccia B; Curry B; Woodburn JR; Chesterson G; Tucker H
J Endocrinol; 1987 Jun; 113(3):R7-9. PubMed ID: 3625091
[TBL] [Abstract][Full Text] [Related]
13. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
Steinsapir J; Mora G; Muldoon TG
Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
[TBL] [Abstract][Full Text] [Related]
14. Endocrine profile of Win 49596 in the rat: a novel androgen receptor antagonist.
Snyder BW; Winneker RC; Batzold FH
J Steroid Biochem; 1989 Dec; 33(6):1127-32. PubMed ID: 2615357
[TBL] [Abstract][Full Text] [Related]
15. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
[TBL] [Abstract][Full Text] [Related]
16. Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats.
Cónsole GM; Jurado SB; Rulli SB; Calandra RS; Gómez Dumm CL
Cells Tissues Organs; 2001; 169(1):64-72. PubMed ID: 11340263
[TBL] [Abstract][Full Text] [Related]
17. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
[TBL] [Abstract][Full Text] [Related]
18. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
19. Comparison of anti-androgenic activity of flutamide, vinclozolin, procymidone, linuron, and p, p'-DDE in rodent 10-day Hershberger assay.
Kang IH; Kim HS; Shin JH; Kim TS; Moon HJ; Kim IY; Choi KS; Kil KS; Park YI; Dong MS; Han SY
Toxicology; 2004 Jul; 199(2-3):145-59. PubMed ID: 15147789
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and Casodex on the reproductive system of the adult male rat.
Chandolia RK; Weinbauer GF; Simoni M; Behre HM; Nieschlag E
Acta Endocrinol (Copenh); 1991 Nov; 125(5):547-55. PubMed ID: 1759544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
